Natural ghrelin in advanced cancer patients with cachexia, a case series
| Autor: | Florian Strasser, David Blum, Thomas Hundsberger, Susanne de Wolf-Linder, Michael Brändle, Rolf Oberholzer |
|---|---|
| Přispěvatelé: | University of Zurich, Blum, David |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Cachexia media_common.quotation_subject Appetite 610 Medicine & health Diseases of the musculoskeletal system Gastroenterology 616: Innere Medizin und Krankheiten Eating 03 medical and health sciences 0302 clinical medicine 2732 Orthopedics and Sports Medicine 2737 Physiology (medical) Growth hormone secretagogue Neoplasms Physiology (medical) Internal medicine Clinical endpoint medicine Humans Orthopedics and Sports Medicine Aged media_common business.industry QM1-695 digestive oral and skin physiology Cancer cachexia Muscle mass Original Articles Middle Aged medicine.disease Advanced cancer 10044 Clinic for Radiation Oncology Ghrelin 030104 developmental biology RC925-935 Tolerability 030220 oncology & carcinogenesis Human anatomy Toxicity Original Article Corrigendum business |
| Zdroj: | Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 2, Pp 506-516 (2021) J Cachexia Sarcopenia Muscle Journal of Cachexia, Sarcopenia and Muscle |
| DOI: | 10.5167/uzh-208504 |
| Popis: | BACKGROUND Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed a dose-finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients. METHODS Advanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self-injected ghrelin twice daily for 4 days followed by a wash-out period. After reaching the primary endpoint, maximal NI (minimal dose for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parameters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks. RESULTS Ten patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end-of study visit. Ghrelin was well tolerated with variable results on appetite and eating-related symptoms but a positive effect in the narratives. Mean Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with baseline, t(5) = 5.98, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|